StoreGene
Integrating Genome into clinical decision support for prevention, diagnostics and treatment for a patient’s entire lifetime. .
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
N/A | Support Program | ||
| Total Funding | 000k | ||
Related Content
StoreGene, a London-based health technology company founded in 2005, provides a Clinical Genomic Operating System (CGOS) designed to integrate genomic data into clinical practice. The company’s foundations are built upon the extensive cardiovascular genetics research of Chief Scientific Officer, Professor Steve Humphries, and the commercial direction of UCL Entrepreneur in Residence, Dr. Dan Brown. Mark Bartlett, who joined as CEO in 2020, brings a background in pharmacogenetics and has guided the company's transition from laboratory testing to a cloud-based digital health platform. This strategic shift was supported by an InnovateUK SMART grant awarded in 2021.
The firm’s core offering is a platform that combines whole genome sequencing (WGS) with a sophisticated bioinformatics system and genomic counseling services. It serves healthcare providers, enabling them to order a single WGS test and gain ongoing clinical insights throughout a patient's life. StoreGene manages the entire process, from sequencing and data storage to generating clinician-led reports in areas such as cardiovascular health, hereditary cancer, pharmacogenomics, and nutrigenetics. The company emphasizes a clinician-first model, where reports are shared with the medical professional to interpret and discuss with the patient.
The CGOS platform utilizes Clinical Genomic Analysis Templates (CGATs) to analyze a patient's whole genome and produce detailed clinical reports rapidly. This system aims to address the cost, speed, and complexity of using genetics in healthcare. By analyzing the entire genome, including non-coding regions, StoreGene's service offers a more comprehensive diagnostic yield compared to whole exome sequencing. A key feature is the ability to reanalyze the genomic data as new research emerges, providing updated insights over time. The business generates revenue by providing these whole genome analysis services to a global client base of clinics and healthcare organizations in regions including Europe, Asia, and the Middle East.
Keywords: whole genome sequencing, clinical genomics, bioinformatics, pharmacogenomics, personalized medicine, healthtech, genetic testing, cardiovascular genetics, digital health, genomic data analysis